Nephrotic Syndrome Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB

Nephrotic Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Nephrotic Syndrome treatment therapies, analyzes DelveInsight.

Nephrotic Syndrome Overview:

**Nephrotic Syndrome** is a collection of symptoms that indicate the kidneys are not functioning properly. These symptoms typically include high levels of protein in the urine, low levels of protein in the blood, elevated blood fats or cholesterol, and swelling in various parts of the body. While anyone can develop nephrotic syndrome, it is slightly more prevalent in men than in women. In children, it most often appears between the ages of 2 and 6.

In adults, the most common primary cause of nephrotic syndrome is **focal segmental glomerulosclerosis (FSGS)**, a kidney disease that can only be definitively diagnosed through a **kidney biopsy**. Unfortunately, even with treatment, many individuals with FSGS progress to **kidney failure**, requiring **dialysis** or a **kidney transplant** to survive. However, there's still a risk that FSGS may return after transplant, potentially leading to the loss of the new kidney.

Download our report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Nephrotic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nephrotic Syndrome Therapeutics Market.

Key Takeaways from the Nephrotic Syndrome Pipeline Report

DelveInsight's Nephrotic Syndrome pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Nephrotic Syndrome treatment.
In March 2025, the FDA approved scPharmaceuticals' supplemental New Drug Application (sNDA) to expand the indication of FUROSCIX (furosemide injection) for the treatment of edema in adult patients with chronic kidney disease (CKD), including those with nephrotic syndrome. FUROSCIX is a subcutaneous furosemide injection, previously approved for use in chronic heart failure patients. This expansion aims to address fluid overload in CKD patients, a common and serious complication associated with the disease. ​
In March 2025, ANI Pharmaceuticals announced FDA approval of a new prefilled syringe presentation of Purified Cortrophin Gel (repository corticotropin injection). This formulation is indicated for several conditions, including inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. ​
Key Nephrotic Syndrome companies such as GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others are evaluating new drugs for Nephrotic Syndrome to improve the treatment landscape.
Promising Nephrotic Syndrome pipeline therapies in various stages of development include Belimumab, and others.

Nephrotic Syndrome Pipeline Analysis
The Nephrotic Syndrome pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Nephrotic Syndrome Market.

Categorizes Nephrotic Syndrome therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Nephrotic Syndrome drugs under development based on:

Stage of development

Nephrotic Syndrome Route of administration

Target receptor

Monotherapy vs. combination therapy

Nephrotic Syndrome Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Nephrotic Syndrome Licensing agreements

Funding and investment activities supporting future Nephrotic Syndrome market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/nephrotic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Nephrotic Syndrome Emerging Drugs

Belimumab: GlaxoSmithKline

Nephrotic Syndrome Companies

There are around three or more major companies currently working on developing treatments for Nephrotic Syndrome. Among them, GlaxoSmithKline has a drug candidate that has reached the most advanced stage of development so far-Phase II clinical trials.

DelveInsight's report covers around 3+ products under different phases of Nephrotic Syndrome clinical trials like

Nephrotic Syndrome Late stage Therapies (Phase III)
Nephrotic Syndrome Mid-stage Therapies (Phase II)
Nephrotic Syndrome Early-stage Therapies (Phase I)
Nephrotic Syndrome Pre-clinical and Nephrotic Syndrome Discovery stage Therapies
Nephrotic Syndrome Discontinued & Inactive Therapies

Nephrotic Syndrome pipeline report provides the Nephrotic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Nephrotic Syndrome Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nephrotic Syndrome Therapies and Key Nephrotic Syndrome Companies: Nephrotic Syndrome Clinical Trials and recent advancements https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Nephrotic Syndrome Pipeline Therapeutic Assessment
• Nephrotic Syndrome Assessment by Product Type
• Nephrotic Syndrome By Stage
• Nephrotic Syndrome Assessment by Route of Administration
• Nephrotic Syndrome Assessment by Molecule Type

Download Nephrotic Syndrome Sample report to know in detail about the Nephrotic Syndrome treatment market @ Nephrotic Syndrome Therapeutic Assessment https://www.delveinsight.com/sample-request/nephrotic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Nephrotic Syndrome Current Treatment Patterns
4. Nephrotic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Nephrotic Syndrome Late-Stage Products (Phase-III)
7. Nephrotic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Nephrotic Syndrome Discontinued Products
13. Nephrotic Syndrome Product Profiles
14. Nephrotic Syndrome Key Companies
15. Nephrotic Syndrome Key Products
16. Dormant and Discontinued Products
17. Nephrotic Syndrome Unmet Needs
18. Nephrotic Syndrome Future Perspectives
19. Nephrotic Syndrome Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Nephrotic Syndrome Pipeline Reports Offerings: https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.